Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
grade C 20.12 2.81% 0.55
IOVA closed up 2.81 percent on Monday, October 21, 2019, on 82 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IOVA trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish 3.44%
MACD Bullish Signal Line Cross Bullish 3.44%
Pocket Pivot Bullish Swing Setup 3.44%
Stochastic Buy Signal Bullish 9.35%

Older signals for IOVA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Medicine Biopharmaceutical Cancer Clinical Medicine Immunotherapy Oncology Cancer Treatments Cancer Immunotherapy Antineoplastic Drugs Melanoma Cell Therapy Solid Tumor Metastatic Melanoma Adoptive Cell Transfer Cancer Immunotherapy Products Head And Neck Cancers Breast And Lung Cancer National Cancer Institute Ocular Melanoma Treatment Of Metastatic Melanoma
Is IOVA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 26.59
52 Week Low 7.26
Average Volume 1,261,037
200-Day Moving Average 16.0558
50-Day Moving Average 19.8589
20-Day Moving Average 18.8223
10-Day Moving Average 18.694
Average True Range 0.9146
ADX 19.5
+DI 23.4952
-DI 18.7664
Chandelier Exit (Long, 3 ATRs ) 18.9262
Chandelier Exit (Short, 3 ATRs ) 20.4138
Upper Bollinger Band 20.2844
Lower Bollinger Band 17.3602
Percent B (%b) 0.94
BandWidth 15.535827
MACD Line -0.2601
MACD Signal Line -0.4855
MACD Histogram 0.2255
Fundamentals Value
Market Cap 1.44 Billion
Num Shares 71.5 Million
EPS -2.08
Price-to-Earnings (P/E) Ratio -9.67
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.49
Resistance 3 (R3) 21.39 20.84 21.26
Resistance 2 (R2) 20.84 20.49 20.89 21.18
Resistance 1 (R1) 20.48 20.28 20.66 20.58 21.11
Pivot Point 19.93 19.93 20.02 19.98 19.93
Support 1 (S1) 19.57 19.58 19.75 19.67 19.13
Support 2 (S2) 19.02 19.37 19.07 19.06
Support 3 (S3) 18.66 19.02 18.98
Support 4 (S4) 18.76